BR112015016033A2 - composições e métodos para tratamento de infecções por bactérias - Google Patents

composições e métodos para tratamento de infecções por bactérias

Info

Publication number
BR112015016033A2
BR112015016033A2 BR112015016033A BR112015016033A BR112015016033A2 BR 112015016033 A2 BR112015016033 A2 BR 112015016033A2 BR 112015016033 A BR112015016033 A BR 112015016033A BR 112015016033 A BR112015016033 A BR 112015016033A BR 112015016033 A2 BR112015016033 A2 BR 112015016033A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
bacterial infections
treating bacterial
treating
Prior art date
Application number
BR112015016033A
Other languages
English (en)
Other versions
BR112015016033A8 (pt
Inventor
Vithalbhai Patel Mahesh
Keshav Deshpande Prasad
Bhagwat Sachin
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of BR112015016033A2 publication Critical patent/BR112015016033A2/pt
Publication of BR112015016033A8 publication Critical patent/BR112015016033A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

resumo patente de invenção: "composições e métodos para tratamento de infecções por bactérias". a invenção refere-se a composições farmacêuticas e métodos para tratamento de infecções por bactérias .
BR112015016033A 2013-01-14 2014-01-13 composições farmacêuticas para tratamento de infecções por bactérias, e seus usos BR112015016033A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN117MU2013 2013-01-14
PCT/IB2014/058221 WO2014108872A1 (en) 2013-01-14 2014-01-13 Compositions and methods for treating bacterial infections

Publications (2)

Publication Number Publication Date
BR112015016033A2 true BR112015016033A2 (pt) 2017-07-11
BR112015016033A8 BR112015016033A8 (pt) 2018-01-23

Family

ID=50336354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016033A BR112015016033A8 (pt) 2013-01-14 2014-01-13 composições farmacêuticas para tratamento de infecções por bactérias, e seus usos

Country Status (12)

Country Link
US (4) US9433613B2 (pt)
JP (1) JP6480870B2 (pt)
KR (1) KR20150089086A (pt)
CN (1) CN104884092A (pt)
AU (2) AU2014206087A1 (pt)
BR (1) BR112015016033A8 (pt)
CA (1) CA2890894C (pt)
MX (1) MX363631B (pt)
RU (1) RU2676482C2 (pt)
SG (1) SG11201503661QA (pt)
WO (1) WO2014108872A1 (pt)
ZA (1) ZA201503474B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ719215A (en) * 2013-10-22 2020-04-24 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
RU2705375C2 (ru) 2014-01-21 2019-11-07 Вокхардт Лимитед Фармацевтические композиции, содержащие антибактериальные агенты
EP3131583A1 (en) * 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
US11084833B2 (en) 2016-10-10 2021-08-10 The Johns Hopkins University Antibacterial agents against D,D- and L,D-transpeptidases
CN107823213A (zh) * 2017-09-16 2018-03-23 安徽华澳生物技术有限公司 一种肉猪抗生素药物
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
EP1755661B1 (en) * 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
PL1776109T3 (pl) * 2004-08-13 2009-06-30 Schering Plough Ltd Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid
WO2007129176A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

Also Published As

Publication number Publication date
US20180263969A1 (en) 2018-09-20
AU2017203932A1 (en) 2017-07-06
CN104884092A (zh) 2015-09-02
US20160199360A1 (en) 2016-07-14
ZA201503474B (en) 2016-11-30
RU2676482C2 (ru) 2018-12-29
CA2890894A1 (en) 2014-07-17
US9636331B2 (en) 2017-05-02
MX2015008486A (es) 2015-09-10
RU2015134149A (ru) 2017-02-16
JP2016504411A (ja) 2016-02-12
SG11201503661QA (en) 2015-06-29
CA2890894C (en) 2019-06-11
KR20150089086A (ko) 2015-08-04
WO2014108872A1 (en) 2014-07-17
BR112015016033A8 (pt) 2018-01-23
MX363631B (es) 2019-03-29
US9433613B2 (en) 2016-09-06
US20170172994A1 (en) 2017-06-22
AU2014206087A1 (en) 2015-05-28
US20160045480A1 (en) 2016-02-18
AU2017203932B2 (en) 2019-02-14
JP6480870B2 (ja) 2019-03-13

Similar Documents

Publication Publication Date Title
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
EA201691534A1 (ru) Лечение устойчивых угрей
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
PH12016500207A1 (en) Anti-infective compounds
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
WO2015003816A3 (en) Cystobactamides
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA202090683A3 (ru) Способы и композиции для лечения рака
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
BR112014025041B8 (pt) Composição farmacêutica
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016501988A1 (en) Antibacterial compounds
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
ZA201608607B (en) Novel fluoroquinolones and use thereof to treat bacterial infections

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL